We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Harbour BioMed announced the dosing of the first patient in the Phase III clinical trial of its global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye ...
Harbour BioMed today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with ...
Harbour BioMed (HBM) announced that the company will present the phase II clinical trial results of Tanfanercept (HBM9036) at the 25th Congress of Chinese Ophthalmological Society (CCOS) held in Xiamen from the 19th to 22nd November.